Our study grants the analysis of a larger number of patients with MDS/AML under hypomethylating therapy or conventional care regimens to further support the observation that CDKN1C mRNA might help predict 5-azacytidine efficacy. Here, CDKN1C is linked to acute myeloid leukemia.